TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

Table 6 Multivariate Cox regression analysis for clinicopathological features and selected genotypes

Variable	HR	DFS 95%CI	P value	HR	OS 95%CI	P value
Stage III vs I and II	2.432	1.279-4.625	0.007
Grade III and IV vs I and II	1.715	0.951-3.091	0.073	1.860	0.982-3.525	0.057
TYMS 5’UTR groups			0.031			0.052
A	3.122	1.193-8.169	0.020	2.715	1.093-6.739	0.031
B	1			1
C	2.919	1.258-6.772	0.013	2.540	1.098-5.876	0.029
TYMS 3’UTR groups
A (without ins/LOH)	1
B (ins/LOH)	4.124	1.744-9.753	0.001	3.335	1.474-7.548	0.004
BRAF V600E mutation				4.500	1.241-16.32	0.022

DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; TYMS: Thymidylate synthase gene; UTR: Untranslated region; LOH: Loss of heterozygosity.